Amyloid-peptide vaccinations reduce β-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice

American Journal of Pathology

Volumn 175, Issue 5, 2009, Pages 2099-2110

  Liu, Bingqian ^a,b   Rasool, Suhail ^a   Yang, Zhikuan ^b   Glabe, Charles G ^a   Schreiber, Steven S ^a,c   Ge, Jian ^b   Tan, Zhiqun ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PEPTIDE VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CELL INFILTRATION; CONTROLLED STUDY; IMMUNOREACTIVITY; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINITIS; VACCINATION; VASCULAR AMYLOIDOSIS;

EID: 73649135004     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090159     Document Type: Article

References (70)

1. Yankner BA, Lu T, Loerch P: The aging brain. Annu Rev Pathol 2008, 3:41-66
2. Greenberg SM: Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998, 51:690-694
3. Heneka MT, O'Banion MK: Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007, 184:69-91
4. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356
5. Yankner BA, Lu T: Amyloid β-protein toxicity and the pathogenesis of Alzheimer's disease. J Biol Chem 2009, 4755-4759
6. Mattson MP: Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639
7. Head E, Lott IT: Down syndrome and β-amyloid deposition. Curr Opin Neurol 2004, 17:95-100
8. Pache M, Smeets CH, Gasio PF, Savaskan E, Flammer J, Wirz-Justice A, Kaiser HJ: Colour vision deficiencies in Alzheimer's disease. Age Ageing 2003, 32:422-426
9. Chan D, Crutch SJ, Warrington EK: A disorder of colour perception associated with abnormal colour after-images: a defect of the primary visual cortex. J Neurol Neurosurg Psychiatry 2001, 71:515-517
10. Lakshminarayanan V, Lagrave J, Kean ML, Dick M, Shankle R: Vision in dementia: contrast effects. Neurol Res 1996, 18:9-15
11. Mendola JD, Cronin-Golomb A, Corkin S, Growdon JH: Prevalence of visual deficits in Alzheimer's disease. Optom Vis Sci 1995, 72:155-167
12. Whittaker KW, Burdon MA, Shah P: Visual field loss and Alzheimer's disease. Eye 2002, 16:206-208
13. Tetewsky SJ, Duffy CJ: Visual loss and getting lost in Alzheimer's disease. Neurology 1999, 52:958-965
14. Butter CM, Trobe JD, Foster NL, Berent S: Visual-spatial deficits expalin visual symptoms in Alzheimer's disease. Am J Ophthalmol 1996, 122:97-105
15. Katz B, Rimmer S: Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 1989, 34:31-43
16. Iseri PK, Altinas O, Tokay T, Yuksel N: Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 2006, 26:18-24
17. Blanks JC, Hinton DR, Sadun AA, Miller CA: Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res 1989, 501:364-372
18. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J: Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2007, 420:97-99
19. Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G: Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 2006, 67:1852-1854
20. Tsai CS, Ritch R, Schwartz B, Lee SS, Miller NR, Chi T, Hsieh FY: Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Ophthalmol 1991, 109:199-204
21. Hinton DR, Sadun AA, Blanks JC, Miller CA: Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 1986, 315:485-487
22. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, Ransom NL, Tahzib NG, Reitsamer HA, Levkovitch-Verbin H, Quigley HA, Zack DJ: Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002, 43:1077-1087
23. Nelson GA, Edward DP, Wilensky JT: Ocular amyloidosis and secondary glaucoma. Ophthalmology 1999, 106:1363-1366
24. Frederikse PH, Ren XO: Lens defects and age-related fiber cell degeneration in a mouse model of increased AβPP gene dosage in Down syndrome. Am J Pathol 2002, 161:1985-1990
25. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Jr., Bush AI: Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 2003, 361:1258-1265
26. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S: β-Amyloid deposition and functional impairment in the retina of the APPswe/PS1δE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 2009, 50:793-800
27. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102
28. Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, Cribbs DH, Glabe CG, Tenner AJ: Novel Aβ peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation 2005, 2:28
29. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG: Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007, 2:18
30. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489
31. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562
32. Kayed R, Glabe CG: Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol 2006, 413:326-344
33. Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, Almeida OF: The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry 2009, 14:95-105
34. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL: Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 1988, 331:528-530
35. Sisodia SS, Price DL: Role of the β-amyloid protein in Alzheimer's disease. FASEB J 1995, 9:366-370
36. Jung SS, Gauthier S, Cashman NR: β-Amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. Neurobiol Aging 1999, 20:249-257
37. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD: Correlation between Aβx-40-. Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch Neurol 2001, 58:2025-2032
38. Viale G, Gambacorta M, Coggi G, Dell'Orto P, Milani M, Doglioni C: Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch A Pathol Anat Histopathol 1991, 418:339-348
39. Sarthy PV, Fu M, Huang J: Developmental expression of the glial fibrillary acidic protein (GFAP) gene in the mouse retina. Cell Mol Neurobiol 1991, 11:623-637
40. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S: Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 1998, 57:1-9
41. Goedert M, Jakes R, Vanmechelen E: Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 1995, 189:167-169
42. Uchihara T, Akiyama H, Kondo H, Ikeda K: Activated microglial cells are colocalized with perivascular deposits of amyloid-β protein in Alzheimer's disease brain. Stroke 1997, 28:1948-1950
43. Tan Z, Sankar R, Tu W, Shin D, Liu H, Wasterlain CG, Schreiber SS: Immunohistochemical study of p53-associated proteins in rat brain following lithium-pilocarpine status epilepticus. Brain Res 2002, 929:129-138
44. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT: APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:965-973
45. Ning A, Cui J, To E, Ashe KH, Matsubara J: Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 2008, 49:5136-5143
46. Akiyama H, Mori H, Saido T, Kondo H, Ikeda K, McGeer PL: Occurrence of the diffuse amyloid β-protein (Aβ) deposits with numerous Aβ-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia 1999, 25:324-331
47. Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T: β-Amyloid deposits in transgenic mice expressing human β-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 2001, 104:299-310
48. Otth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C, Maccioni RB: AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 2002, 4:417-430
49. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M: Brain Aβ amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol 2001, 194:500-506
50. Masliah E, Sisk A, Mallory M, Games D: Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J Neuropathol Exp Neurol 2001, 60:357-368
51. Wisniewski HM, Vorbrodt AW, Wegiel J: Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann NY Acad Sci 1997, 826:161-172
52. Castellani RJ, Smith MA, Perry G, Friedland RP: Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging 2004, 25:599-602; discussion 603-594
53. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM: The cerebral β-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006, 16:30-39
54. Miller NR: Alzheimer's disease, optic neuropathy, and selective ganglion cell damage. Ophthalmology 1990, 97:7-8
55. Keri S, Antal A, Kalman J, Janka Z, Benedek G: Early visual impairment is independent of the visuocognitive and memory disturbances in Alzheimer's disease. Vision Res 1999, 39:2261-2265
56. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F: Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 2001, 112:1860-1867
57. Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH: Mannan-Aβ28 conjugate prevents Aβ-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation 2008, 5:42
58. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN: Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 2007, 144:950-960
59. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO: Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008, 34:131-144
60. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA: Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310
61. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919
62. Garcia-Alloza M, Ferrara BJ, Dodwell SA, Hickey GA, Hyman BT, Bacskai BJ: A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol Dis 2007, 28:286-292
63. Monsonego A, Weiner HL: Immunotherapeutic approaches to Alzheimer's disease. Science 2003, 302:834-838
64. Le Cudennec C, Faure A, Ly M, Delatour B: One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice, Genes Brain Behav 2008, 7(Suppl 1):83-91
65. Hale G, Good M: Impaired visuospatial recognition memory but normal object novelty detection and relative familiarity judgments in adult mice expressing the APPswe Alzheimer's disease mutation. Behav Neurosci 2005, 119:884-891
66. Brown RE, Wong AA: The influence of visual ability on learning and memory performance in 13 strains of mice. Learn Mem 2007, 14:134-144
67. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ: Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 1987, 104:113-120
68. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH: Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL, Neurobiol Aging 1996, 17:385-395
69. Strenn K, Dal-Bianco P, Weghaupt H, Koch G, Vass C, Gottlob I: Pattern electroretinogram and luminance electroretinogram in Alzheimer's disease. J Neural Transm Suppl 1991, 33:73-80
70. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL: Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007, 48:2285-2289